Let the speculation about the phase-2 trial design begin!
I think it’s probable that one of GENR’s phase-2 trial*s* will be large and will have a control arm (Visudyne and/or placebo), so it can serve as one of the two large, “well-controlled” trials the FDA requires for approval. This is the approach taken by Alcon with Retaane.